Our results confirm also the results of Jorgensen and colleagues which showed that the predominant effect of imatinib and nilotinib on CD34+ CML cells is anti-proliferative rather than pro apoptotic. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.